ClinicalTrials.Veeva

Menu

The Role of Visfatin in Obesity and Periodontal Disease

G

Gazi University

Status

Completed

Conditions

Periodontitis
Obesity

Treatments

Procedure: Phase I Periodontal therapy
Dietary Supplement: Metabolic control

Study type

Observational

Funder types

Other

Identifiers

NCT03470987
OBESITY

Details and patient eligibility

About

Visfatin is an adipokine that plays an important role in immune functions as a growth factor, enzyme, and proinflammatory mediator. The investigators aimed to determine the levels of visfatin, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in gingival crevicular fluid (GCF) in both obese/non-obese patients, with/without generalized chronic periodontitis (GCP). Patients were categorized as obese (O) (n=31) or non-obese (nO) (n=19). Groups were divided into four subgroups according to periodontal conditions: (1) periodontally healthy without obesity (nO-Ctrl); (2) GCP without obesity (nO-CP); (3) periodontally healthy with obesity (O-Ctrl); and (4) GCP with obesity (O-CP). Demographic variables and anthropometric and laboratory data were recorded. Periodontal measurements were recorded at baseline and 3rd months after either non-surgical periodontal treatment or calorie restricted diet therapy. At the same time GCF samples were taken from patients to analyze TNF-alpha, IL-6, and visfatin levels.

Full description

Overweightness and obesity are defined as the accumulation of fat in body tissues that might impair overall health. Adults are considered overweight if their body mass index (BMI, calculated as weight in kg/[height in meters]2) is ≥ 25 and obese if BMI ≥ 30 kg/m2. The prevalence of overweightness and obesity has increased worldwide during recent decades.

Obesity is usually related to a chronic low-grade systemic inflammation resulting in significant changes in the concentrations of cytokines and hormones, which subsequently leads to the development of obesity-linked disorders, including insulin resistance, type II diabetes, cardiovascular diseases, dyslipidemia, and metabolic syndrome. Since the host response is among the most crucial factors affecting the pathogenesis of periodontal disease, multiple studies have addressed the possible associations between BMI, overweightness, obesity, diabetes, the serum level of lipids, cholesterol, and periodontal breakdown, with mixed results. Many studies have demonstrated a positive association between obesity and periodontitis and suggested that obesity-related inflammation might promote periodontitis by secretion of inflammatory markers by the adipose tissue, which might subsequently increase gingival inflammation. The association between obesity and periodontal disease is based on the amassing of white adipose tissue (WAT) and increased secretion levels of adipokines from WAT.

WAT is an energy storage organ with some metabolic activities, participating in the endocrine and secretory systems. WAT secretes several immune-modulatory adipokine molecules, such as adiponectin, leptin, visfatin, resistin, chemerin, tumor necrosis factor-alpha (TNF-alpha), interleukin-1β (IL-1β), and interleukin-6 (IL-6). It has been found that these molecules are involved in a wide range of physiologic and pathologic processes, including immunity and inflammation. Thus, cytokines and hormones released from adipose tissue might play a role in the destruction of periodontal tissue by inducing hyperinflammatory responses.

Visfatin is a multi-potential mediator that functions as a growth factor, cytokine, an enzyme with a role in energy metabolism, and as a proinflammatory mediator. It is mainly released from adipose tissue, especially from macrophages, and can also be released from lymphocytes, dendritic, muscle, and bone marrow cells. Visfatin has an important role in the regulation of the immune response. Visfatin inhibits neutrophil apoptosis during inflammation and increases TNF-alpha, IL-1β, and IL-6 levels. The expression of visfatin is increased under inflammatory conditions, such as rheumatoid arthritis, cardiovascular diseases, type-II diabetes mellitus, and periodontal disease.

Although several studies have demonstrated the relationship between periodontitis and obesity, no study has evaluated the levels of visfatin in gingival crevicular fluid (GCF) in obese individuals with periodontitis. Increased adipocytes levels, such as visfatin, cause secretion of cytokines, which are known to play an important role in periodontitis, and might trigger periodontitis formation and development.

Therefore, the main objective of this study was to analyze the levels of visfatin, IL-6, and TNF-alpha in obese and non-obese individuals, with or without generalized chronic periodontitis (GCP). Secondarily, the investigators aimed to evaluate metabolic and clinical periodontal parameters, and also clarify the relationship between these parameters and adipocytokines. The hypothesis is that adipocytokine molecules are involved in the pathogenesis of inflammatory diseases; if true, individuals who are obese with periodontitis would present increased levels of visfatin, IL-6, and TNF-alpha in their GCF.

Enrollment

50 patients

Sex

All

Ages

20 to 68 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • having > 22 natural teeth
  • no systemic diseases
  • having good cooperation
  • having BMI > 30
  • waist circumference > 88 cm for females for obese patients
  • waist circumference > 102 cm for males for obese patients
  • age > 20 years

Exclusion criteria

  • presence of localized chronic periodontitis
  • received periodontal therapy/surgery in the previous 6 months
  • pregnancy
  • use of any hormone therapy
  • history of antibiotic or anti-inflammatory drugs therapy within the previous 6 months
  • current and former smoker
  • lactation
  • presence of aggressive periodontitis
  • presence of periapical pathologies

Trial design

50 participants in 4 patient groups

Group 1:nO-Ctrl
Description:
Non-obese patients without generalized chronic periodontitis who were undergone Phase I periodontal therapy
Treatment:
Procedure: Phase I Periodontal therapy
Group 2:nO-CP
Description:
Non-obese patients with generalized chronic periodontitis who were undergone Phase I periodontal therapy
Treatment:
Procedure: Phase I Periodontal therapy
Group 3: O-Ctrl
Description:
Obese patients without generalized chronic periodontitis who were undergone metabolic control and Phase I periodontal therapy
Treatment:
Dietary Supplement: Metabolic control
Procedure: Phase I Periodontal therapy
Group 4: O-CP
Description:
Obese patients with generalized chronic periodontitis who were undergone metbolic control and Phase I periodontal therapy
Treatment:
Dietary Supplement: Metabolic control
Procedure: Phase I Periodontal therapy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems